WP
QNCX icon

Woodline Partners’s Quince Therapeutics QNCX Stock Holding History

Woodline Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,000
Closed -$527K – 1125
2026
Q1 		$527K Buy
26,000
+16,292
+168% +$3.27M ﹤0.01% 955
2025
Q4 		$6.5M Buy
+9,708
New +$4.88M 0.03% 565

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners's QNCX Position: Q2 2026 in Review

Woodline Partners sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 26,000 shares — an estimated $527K sold.

Woodline Partners first reported a position in QNCX in Q4 2025 and held it in 2 quarters. The position peaked at $6.5M in Q4 2025. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Woodline Partners reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 26,000 Quince Therapeutics shares in Q2 2026, an estimated $527K.
  • Woodline Partners first reported a position in Quince Therapeutics in Q4 2025 and held it in 2 quarters.
  • Woodline Partners's Quince Therapeutics position peaked at $6.5M in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.